ADVANCED GASTRIC ADENOCARCINOMA
Clinical trials for ADVANCED GASTRIC ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new ADVANCED GASTRIC ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for ADVANCED GASTRIC ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug targets Hard-to-Treat cancers in early trial
Disease control OngoingThis study tests an experimental drug called M9140 in people with advanced solid tumors (gastric, lung, or pancreatic cancer) that have a specific protein (CEACAM5). The drug is designed to deliver a toxin directly to cancer cells. About 250 adults will receive the drug alone or …
Matched conditions: ADVANCED GASTRIC ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New cocktail aims to shrink Hard-to-Treat stomach tumors
Disease control OngoingThis phase 2 trial is testing a combination of three drugs—anlotinib, TQB2450, and the SOX chemotherapy regimen—as a first treatment for advanced stomach or gastroesophageal junction cancer that has low PD-L1 expression. The study involves 37 participants and aims to see how well…
Matched conditions: ADVANCED GASTRIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Yongxu Jia • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Triple drug cocktail targets tough stomach cancer
Disease control OngoingThis phase 2 study is testing a combination of three drugs—paclitaxel (a chemotherapy), pembrolizumab (an immunotherapy), and olaparib (a targeted therapy)—in 36 adults with advanced gastric or gastroesophageal cancer that has worsened after one prior treatment. The goal is to se…
Matched conditions: ADVANCED GASTRIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New immunotherapy cocktail targets Hard-to-Treat cancers
Disease control OngoingThis Phase 2 trial tests whether adding an experimental immunotherapy drug (SHR-8068) to a standard immunotherapy (adebrelimab) plus chemotherapy can shrink tumors better than standard treatment alone in people with advanced stomach or esophageal cancer. About 153 participants wi…
Matched conditions: ADVANCED GASTRIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 13:05 UTC